Search research articles
Contact Us
Filters
Showing results (131-140 of 179) with videos related to
Page
of 18
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2024
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review
Yang Xia, Kaiwen Wang, Jing Zhao, et al.
JTO Clinical and Research Reports
|
April 27, 2026
Durvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD
Byoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 20, 2018
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLC
Xiuning Le, Sonam Puri, Marcelo V Negrao, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Incorporating an NCCN-Based Systemic Therapy CNS Activity Score Into SRS Decision-Making for Patients With 5 or More Brain Metastases
Thomas H Beckham, Stephanie O Dudzinski, Michael K Rooney, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 24, 2025
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report
Bingnan Zhang, Komal B Shah, Mitchell Parma, et al.
Cell Reports. Medicine
|
November 9, 2023
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
Xiuning Le, Luis G Paz-Ares, Jan Van Meerbeeck, et al.
Cancer Immunology, Immunotherapy : CII
|
March 9, 2021
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma
Pedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Cancer Cell
|
February 14, 2023
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Monique B Nilsson, Yan Yang, Simon Heeke, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 4, 2026
CT-Based Deep Foundation Model for Predicting Immune Checkpoint Inhibitor-Induced Pneumonitis Risk in Lung Cancer
Amgad Muneer, Eman Showkatian, Yuliya Kitsel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC
Kaiwen Wang, Robyn Du, Nathaniel J Myall, et al.
Page
of 18
Search research articles
Search
Showing results (131-140 of 179) with videos related to
Sort By:
Page
of 18
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2024
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review
Yang Xia, Kaiwen Wang, Jing Zhao, et al.
JTO Clinical and Research Reports
|
April 27, 2026
Durvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD
Byoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 20, 2018
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLC
Xiuning Le, Sonam Puri, Marcelo V Negrao, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Incorporating an NCCN-Based Systemic Therapy CNS Activity Score Into SRS Decision-Making for Patients With 5 or More Brain Metastases
Thomas H Beckham, Stephanie O Dudzinski, Michael K Rooney, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 24, 2025
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report
Bingnan Zhang, Komal B Shah, Mitchell Parma, et al.
Cell Reports. Medicine
|
November 9, 2023
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
Xiuning Le, Luis G Paz-Ares, Jan Van Meerbeeck, et al.
Cancer Immunology, Immunotherapy : CII
|
March 9, 2021
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma
Pedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Cancer Cell
|
February 14, 2023
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Monique B Nilsson, Yan Yang, Simon Heeke, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 4, 2026
CT-Based Deep Foundation Model for Predicting Immune Checkpoint Inhibitor-Induced Pneumonitis Risk in Lung Cancer
Amgad Muneer, Eman Showkatian, Yuliya Kitsel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC
Kaiwen Wang, Robyn Du, Nathaniel J Myall, et al.
Page
of 18